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Abstract: The existence of specific cellular subpopulations within 
primary tumors with increased tumorigenic potential and chemother-
apy resistance (tumor-initiating cells, TICs) holds great therapeutic 
implications. Resistant cells can remain quiescent for long periods 
and be responsible for local relapses and metastasis. We and others 
have previously described in non–small-cell lung cancer the presence 
of cisplatin-resistant CD133+ cells with tumor-initiating potential and 
co-expression of CXCR4 as possible indicator of TICs with dissemi-
nating potential. In this study, we report, by in vitro cell fate tracing 
systems, heterogeneity within the TIC compartment with a highly 
quiescent pool and a slowly dividing subpopulation, both contain-
ing CD133+ cells but respectively enriched for CD133+/CXCR4- and 
CD133+/CXCR4+ cells. Pretreatment with differentiating agent all-
trans retinoic acid counteracts cisplatin resistance specifically of the 
slowly dividing compartment indicating effect on CD133+/CXCR4+ 
cells. The same effects are appreciable also in vivo in patient-derived 
xenografts, where several cycles of all-trans retinoic acid and cis-
platin treatment are able to stably reduce this fraction of TICs and 
tumor dissemination. Thus, partially affecting the heterogeneous 
TICs compartment, differentiating therapy has promising effects in 
counteracting cisplatin resistance of CD133+ cells, reducing both 
local tumor growth and dissemination. In addition, our approach 
discloses a further level of complexity of chemotherapy-resistant 
CD133+ TICs, revealing phenotypical and functional heterogeneity 
of the cancer stem cell compartment in lung cancer.
Key Words: Non–small-cell lung cancer, Retinoic acid, Cancer stem 
cells dynamics, Cisplatin resistance.
(J Thorac Oncol. 2015;10: 1027–1036)
Non–small-cell lung cancer (NSCLC), representing approximately 80% of all lung cancers, is the main cause 
of cancer-related deaths worldwide. Even though recently 
developed targeted therapies have been shown to provide some 
benefit in predefined subclasses of patients with tumors car-
rying specific mutations, platinum-based chemotherapy still 
represent the standard systemic treatment for NSCLC. 
However, 5-year survival rates have not raised substantially 
in the past decades, remaining as low as 20% for late stage 
disease (III–IV).1 Cisplatin resistance is the consequence of a 
multifactorial event which involves a combination of features, 
such as drug inactivation by detoxifying factors, alterations in 
checkpoint and apoptotic proteins, and variation in intracellu-
lar drug accumulation.2–4 However a rising number of observa-
tions also indicates that, in several tumor types, distinct cellular 
subpopulations persist after treatment and that these cells own 
intrinsic characteristics associated with a stem-like phenotype5 
and can be indicated as cancer stem cells or tumor-initiating 
cells (TICs). TICs characterized by increased tumorigenicity, 
self-renewal ability, and multipotency6,7 have been described 
for several tumor types, such as myeloid leukemia,8 glio-
blastoma,9–11 melanoma,12 and several epithelial cancers13–18 
including lung cancer.19,20 Particularly, lung cancer TICs are 
detected by the expression of cell surface markers as CD133 
or by the high activity of aldehyde dehydrogenase and finally 
by increased capacity to efflux the DNA-binding dye Hoechst 
33342 that define the so-called side population cells.21 Even if 
some controversies are still open about the choice of the most 
appropriate marker to enrich for TICs, almost all published 
studied demonstrating the drug resistance properties of lung 
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TICs reported the enrichment for a fraction of CD133+ cells 
after chemotherapy, indicating the leading role of such cell sub-
set in chemoresistance.22
Furthermore, the stem-like and tumorigenic phenotype 
has been associated to a slow proliferating fraction of cells within 
primary lines or cancer cells.23,24 The peculiar characteristics of 
TICs, and in particular their capability to remain in a quiescent 
state,25 are consistent with a lower susceptibility to replication-
related drugs as previously described also in NSCLC, where 
CD133+ TICs have been reported as being spared by Cisplatin 
treatment.20 Moreover, in vitro CDDP treatment of NSCLC-
derived spheres enriched for TICs induces a replication block 
(G2/M) and a more efficient DNA damage repair that can be pre-
vented by treatment with inhibitor of checkpoint protein kinase 
(Chk1).26 Recently, cancer stem cells (CSC) from NSCLC have 
also been shown to be susceptible to Bcl-XL inhibition indicat-
ing potential therapeutic strategies targeting TICs.27
We reasoned that an efficient strategy to target TICs could 
also rely on their mobilization from the quiescence state inducing 
a chemo-susceptible phenotype, as already proposed and substan-
tiated for leukemic stem cells.28,29 Altogether, this would deplete 
the tumor of its CSCs reservoir preventing relapse, metastasis for-
mation and, eventually, increasing the efficacy of chemotherapy.
In this study, to overcome CDDP resistance of CD133+ 
NSCLC CSCs, we tested the capacity of all-trans retinoic acid 
(ATRA), in vitro and in vivo, to force the TICs fraction to dif-
ferentiate to a more CDDP susceptible phenotype. ATRA has 
been reported to be effective in the cure and prevention of 
many types of cancer (reviewed in 30), however, its differentiat-
ing role against solid tumors CSC’s compartment is still poorly 
explored.31–33 Using in vitro cell fate tracing systems and in vivo 
models of patient-derived xenografts (PDXs),34 we show here 
that ATRA is able to interfere with the dynamics of the CSC 
compartment and prevents chemotherapy-related TICs increase.
MATERIALS AND METHODS
Cell Cultures
LT73 cells were derived in our laboratory from a pri-
mary lung tumor of a 68-year-old Caucasian male patient 
with lung adenocarcinoma. Cells were grown in RPMI-1640 
(Lonza, Basel, Switzerland), supplemented with 10% fetal 
bovine serum (Lonza) and penicillin/streptomycin (Invitrogen, 
Carlsbad, CA) at 37°C with 5% CO
2
.
PKH Labeling
LT73 cells were labeled with PKH67 Fluorescent cell 
linker (Sigma-Aldrich, St. Louis, MO) according to the manu-
facturer’s instruction. In brief, cells were incubated 5 minutes 
at room temperature with PKH67 Dye Solution. Staining was 
stopped adding fetal bovine serum (Lonza) and labeled cells 
were analyzed by flow cytometry at different time points.
Culture of Cancer Tissue-Originated Spheroids
Cancer tissue-originated spheroids (CTOS) culture 
method was adapted from Kondo et al.35
In brief, tumor tissue was mechanically and then enzy-
matically digested in a solution of collagenase IV (5 mg/ml) 
and DNAse (100 U/ml; Sigma Aldrich, St. Louis, MO) in 
DMEM/F12 (Lonza, Verviers, Belgium) for 1 hour at 37°C 
and subsequently filtered through 100-μm and 40-μm cell 
strainers (Becton Dickinson, Franklin Lakes, NJ). The tumor 
tissue organoids retained in the strainer were washed in 30 ml 
of DMEM/F12 and centrifuged at 100g for 5 minutes. Tumor 
organoids were plated in stem cell medium SCM (described in 
20) and in 60 mm Petri dishes. Spheroids appeared in about 3 
days. For culture expansion, spheroids were centrifuged at 100g 
for 5 minutes and incubated with a mild digestion solution of 
DMEM/F12 + collagenase IV 5 mg/ml at 37°C for 5 minutes.
Flow Cytometry Analysis
Single-cell suspensions were washed and incubated in 
staining solution containing 1% BSA and 2 mM ethylene-
diaminetetraacetic acid with specific antibodies at appro-
priate dilutions. For CD133 and CXCR4 staining, 106 cells 
were incubated with phycoerythrin-conjugated anti-CD133/1 
(Miltenyi Biotec, Bergish Gladbach, Germany) and allo-
phycocyanin-conjugated anti-CXCR4 (Becton Dickinson). 
Samples were acquired by FACS Calibur and analyzed with 
FlowJo_V10 software.
For lung dissemination analysis, a morphological gate 
allowing the identification of the highest percentage of human 
tumor cells in murine lungs was identified36 and subsequent 
exclusion for 7-AAD+ dead cells and mouse H2K+ cells was 
performed. This method was able to specifically detect as few 
as 103 single tumor cells in murine lungs.
Patient-Derived Xenograft Tumor Growth
All experiments were carried out with female SCID 
mice, 7–10 weeks old (Charles River Laboratories, Calco, 
Italy). Mice were maintained in laminar flow rooms, with 
constant temperature and humidity. Mice had free access to 
food and water. Experiments were approved by the Ethics 
Committee for Animal Experimentation of the Fondazione 
IRCCS Istituto Nazionale dei Tumori, according to insti-
tutional guidelines. PDXs were established as described.34 
PDX111 (EGFRwt, KRASwt, LKB1wt, HER2wt, PIK3wt, 
BRAFwt) and PDX73 (EGFRwt, KRASwt, LKB1K287X, 
HER2wt, PIK3wt, BRAFwt) were derived from a 77-year-old 
female and a 68-year-old Caucasian male patient, respectively, 
both with lung adenocarcinoma. For pharmacological experi-
ments, mice were randomly distributed into equal groups (five 
mice per group, grafted in both flanks). Mice were treated with 
All-Trans Retinoic Acid (Sigma-Aldrich; 10 mg/kg gavage, 
qd × 5 × 3 weeks) and/or with Cisplatin (Teva, Petach Tikva, 
Israel; 5 mg/kg i.v. q7d × 3).
Immunofluorescence
104 LT73 cells were grown on Lab-Tek (ThermoFisher, 
Waltham, MA) slides and incubated with BSA 2% + NGS 5% 
blocking solution for 30 minutes, incubated with anti-human 
CD133/1 (Miltenyi; Biotec) for 1 hour at RT, then 30' at RT 
with AlexaFluor 488 goat anti human IgG (H+L) (Invitrogen) 
washed in tween 1× and mounted with the VECTASHIELD 
Mounting Medium, containing DAPI (Vector Laboratories, 
Burlingame, CA).
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Statistical Analysis
All data are shown as mean value ± standard error. 
t tests and Fisher exact test have been performed with GraphPad 
Prism 4 Software. p values are represented as follows: 
*: p < 0.05; **: p < 0.01, ***: p < 0.001.
RESULTS
Identification of a Slow Proliferating Fraction 
of NSCLC Cells Enriched for CD133+ TICs 
with High In Vivo Tumorigenic Potential
To investigate the compartment of slow proliferating 
cells and its dynamics in NSCLC, we exploited a general 
cell membrane labeling system (Fluorescent Cell Linker Kit 
PKH67, Sigma-Aldrich, St. Louis, MO), previously reported 
as a useful tool to identify slow proliferating cells37,38 because 
the labeling is progressively diluted through repeated cell 
divisions whereas not proliferating cells maintain it for weeks. 
LT73 primary cell line, established from patient’s lung adeno-
carcinoma, was labeled with PKH67 and label retaining was 
monitored by flow cytometry during serial population dou-
blings (PD). After 10 PDs (PD10) a small amount of labeled 
cells (PKH+) was still appreciable (0.22 ± 0.11%, n = 5 repli-
cates) as confirmed also by immunofluorescence analysis (Fig. 
1A, Supplementary 1a, SDC 1, http://links.lww.com/JTO/
A843). Interestingly, a remarkable enrichment of CD133+ TICs 
was appreciable in the PKH+ subpopulation (200-fold average: 
24.7 ± 4.8% versus 0.12 ± 0.05% in total population, n = 5 rep-
licates; Fig. 1B). Within this subpopulation of quiescent cells, a 
PKH brightest subgroup was recognized (long-term quiescent 
cells, PKH
BRIGHT
) and analysis revealed a further enrichment of 
CD133+ cells (400-fold average: 48.3 ± 7.7 versus 0.12 ± 0.05 
in total population, n = 5 replicates). We previously demon-
strated that CD133+ cells spared by CDDP were particularly 
enriched for the subset co-expressing the chemokine receptor 
CXCR420 that could be involved in dissemination of TICs.36,39 
Interestingly, the observed heterogeneity within the slow pro-
liferating PKH+ cells is mirrored by different distribution of 
CXCR4 co-expressing cells, indeed PKH
BRIGHT
 fraction was 
mainly composed by CD133+/CXCR4− cells (36.1 ± 4.61% 
CD133+/CXCR4− versus 12.22 ± 2.803% CD133+/CXCR4+, 
n = 5, Supplementary 1B, SDC 1, http://links.lww.com/JTO/
A843), conversely an enrichment for CD133+/CXCR4+ cells 
was appreciable in the PKH
DIM
 fraction (short-term quiescent, 
4.1 ± 0.75% CD133+/CXCR4− versus 11.7 ± 2.3% CD133+/
CXCR4+, n = 5, Supplementary 1B, SDC 1, http://links.lww.
com/JTO/A843). PKH
BRIGHT
 cells showed enhanced tumori-
genic potential when injected subcutaneously in SCID mice. 
In this assay, 102 PKH
BRIGHT
, but not 102 PKH
DIM
 cells suc-
cessfully gave rise to fully developed tumors (4/4 take rate, 
average tumor volume of 1000 mm3 reached 60 days after 
injection versus 0/4 take rate; Fig. 1C). Moreover, injection of 
103 PKH
DIM
 cells led to a delayed tumor growth (3/4 take rate 
and tumor growth delayed by 30 days, Fig. 1C). We previously 
reported the increased tumorigenicity of CD133+ compared 
with CD133− cells. As the estimated amount of CD133+ TICs 
(and CD133+/CXCR4+ fraction) was higher in 103 PKH
DIM
 than 
in 102 PKH
BRIGHT
 injected cells, we speculate that the amount 
of CD133+/CXCR4- cells in the PKH
BRIGHT
 subset was respon-
sible for the observed tumor growth (Table 1). A subset of 
PKH retaining, CD133+-enriched population was also detect-
able ex vivo in PDX models. Cells obtained from disaggrega-
tion of PDX samples (PDX111, Fig. 2A and PDX73, Fig. 2B) 
were stained with PKH67 and reinjected subcutaneously in 
the flank of immunocompromised mice. In tumors analyzed 
at different volumes (V
1
 = 250 mm3, V
2
 = 1000 mm3), a small 
fraction of PKH-labeled cells was still detectable and showed 
an enrichment of CD133+ TICs (three- to 50-fold depending 
on the model, Fig. 2), more evident in the PKH
BRIGHT
 fraction 
(up to 115-fold). Thus, PKH labeling led to the identification 
of the heterogeneity of TICs compartment, with more or less 
quiescent CD133+ cells, and, interestingly, suggested heteroge-
neity also within the quiescent fraction. Indeed, the PKH
BRIGHT
 
fraction, few cells which underwent very few replications, was 
mainly composed by CD133+/CXCR4− cells, whereas in the 
PKH
DIM
 fraction, a larger number of cells lying across the qui-
escence–nonquiescence border, CD133+/CXCR4+ cells were 
more represented. The high tumorigenicity of PKH
BRIGHT
 cells 
suggests that quiescent CD133+/CXCR4− cells are the main 
responsible for the observed in vivo growth after subcutane-
ous implantation.
CDDP-Resistant Subpopulation is Highly 
Enriched in Slow Proliferating CD133+ Cells
To further demonstrate the link between quiescence and 
chemoresistance, LT73PKH (PD10) cells were treated with 10 
µM CDDP (LD50) for 72 hours. The PKH-positive fraction 
showed resistance to CDDP treatment, increasing by a 15-fold 
average enrichment (n = 5 replicates; 2.7 ± 0.7% compared 
with 0.22 ± 0.11% PKH+ cells in untreated controls; Fig. 3A). 
CDDP was preferentially active against proliferating PKH
NEG
 
cells as expected but interestingly also on PKH+/CD133- cells. 
Indeed, after CDDP treatment, both PKH
BRIGHT
 and PKH
DIM
 
fractions were almost entirely composed by CD133+ cells (Fig. 
3B) confirming our previous data on resistance of CD133+ 
cells to CDDP treatment.20 Notably, a relevant enrichment of 
CD133+/CXCR4+ cells after CDDP treatment was observed 
in the PKH
DIM
 fraction (Fig. 3B). Taken together, these data 
indicate that the quiescent PKH+/CD133+ subpopulation over-
laps with the already reported cisplatin-resistant CD133+ TICs 
and that different dynamics within PKH subpopulations after 
CDDP treatment are appreciable.
ATRA Pretreatment Partially Reverts 
CDDP-Induced TICs Enrichment In Vitro 
Acting on CD133+/CXCR4+ Cells
To verify the effect of differentiating agent on TICs 
subset, LT73 cell line was treated in vitro with ATRA 10 
µM (every 48 hours, from PD8 to PD10); no effect on cell 
proliferation and viability was observed during treatment 
(Supplementary 3A, SDC 1, http://links.lww.com/JTO/A843), 
and a general decrease in CD133+ percentages was induced, 
even though the only significant effect was observed within 
PKH+/CD133+/CXCR4+ fraction (15.4 ± 1.6% in untreated 
versus 13.6 ± 1.7% in ATRA treated cells, n = 5; p = 0.0192, 
Supplementary 3B, SDC 1, http://links.lww.com/JTO/A843). 
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FIGURE 1.  In vitro identification of a slow proliferating fraction enriched for CD133+ TICs in a NSCLC-derived cell line (LT73). 
PKH67 (Sigma) labeled cells were almost completely labeled at day 0 and progressively lost the labeling. At PD10, a small amount 
of positive cells were still appreciable, both by fluorescence activated cell sorting and immunofluorescence (representative FACS and 
immunofluorescence analysis out of three replicates are shown) (A); CD133+ tumor initiating cells were 200-fold enriched in the 
PKH retaining fraction (24.7 ± 2.8% versus 0.12 ± 0.05%). A representative FACS analysis out of five replicates shows this enrichment 
(upper right box) compared with basal level of CD133+ cells in this cell line (middle left box); the low box shows that CD133+ cells 
enrichment is higher in the most quiescent fraction (PKHBRIGHT, 450-fold enrichment, 55.1 ± 4.5 versus 0.12 ± 0.05), intermediate in 
the PKHDIM fraction (130-fold enrichment, 15.8 ± 3.1 versus 0.12 ± 0.05) and absent in the PKHNEG fraction, data are shown as per-
centage of CD133+ cells, t test p values are represented as: *p < 0.05, **p < 0.01, ***p < 0.001 (B). In vivo injection of PKH-labeled 
cells shows that 100 PKHBRIGHT cells injected subcutaneously in SCID mice (n = 4) are able to give rise to a completely developed 
tumor (1000 mm3). Same tumor growth are not achieved injecting 100 PKHDIM cells, where a delayed tumor growth is appreciable 
after injection of 1000 PKHDIM cells. Tumor take is represented as “number of developed tumors/numbers of injection” (C).
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CDDP treatment in cells previously exposed to ATRA led 
to a less pronounced increase of PKH+ cells compared with 
CDDP-only treated cells (1.8 ± 0.85% versus 2.7 ± 0.7% in 
CDDP-only treated, corresponding to an average preven-
tion of 36.3% of CDDP-induced enrichment, n = 5, Fig. 3A). 
In details, ATRA pretreatment was able to prevent increase 
of CD133+ cells due to CDDP exposure, completely in the 
PKH
NEG
 fraction and partially in the PKH
DIM
 fraction, with-
out affecting the more quiescent PKH
BRIGHT
 fraction (Fig. 3B 
and Supplementary Table 1, SDC 2, http://links.lww.com/
JTO/A844). These in vitro data suggest that the differentiating 
agent is able to sensitize proliferating PKH
NEG
 CD133+ cells to 
CDDP and is also partially able to push a fraction of quiescent 
PKH
DIM
 CD133+ into a cisplatin responsive state, seemingly 
acting on CD133+/CXCR4+ cells, whose increase is totally 
prevented. The same experiment was carried out on ex vivo 
CTOS established from two PDX models. Similarly to in vitro 
results, ATRA treatment induced a slight decrease of TICs 
(from 22% to 19%, corresponding to a 14% decrease com-
pared with untreated CTOS111, whereas a higher effect was 
appreciable in CTOS73, from 0.4% to 0.05%, corresponding 
to a 87.5% decrease compared with untreated) associated with 
a down regulation of stemness genes (Supplementary 3B–D, 
SDC 1, http://links.lww.com/JTO/A843). Moreover, CD133+ 
cells enrichment after CDDP treatment was partially pre-
vented by ATRA also in these ex vivo models (from 29% to 
25% corresponding to a prevention of 57% of CDDP-induced 
enrichment in CTOS111, and from 0.8% to 0.5% correspond-
ing to a prevention of 75% of CDDP-induced enrichment in 
CTOS73, Fig. 3C). Taken together, these in vitro and ex vivo 
data indicate that within the TIC compartment the differentiat-
ing treatment preferentially sensitizes PKH
DIM
 cells, enriched 
in CD133+/CXCR4+ TICs, to CDDP treatment without affect-
ing PKH
BRIGHT
 cells.
TABLE 1.  In Vivo Injection of PKHBRIGHT or PKHDIM-Sorted Cells
N
CD133+ CD133+/CXCR4+ CD133+/CXCR4− In Vivo
% Cells % Cells % Cells Take (%) Growth
BRIGHT
100
4 48.3 ± 7.7 41–55 12.2 ± 2.8 10–15 36.1 ± 5.5 31–41 100 Complete
DIM
1000
4 15.3 ± 2.8 125–180 11.7 ± 2.3 94–140 4.1 ± 0.75 40–42 75 Delayed
DIM
100
4 15.3 ± 2.8 13–18 11.7 ± 2.3 9–14 4.1 ± 0.75 4 0 None
Estimated numbers of CD133+ and CD133+/CXCR4+ cells are higher in the PKH
DIM1000
 fraction than in the PKH
BRIGHT100
 fraction. In contrast, CD133+/CXCR4− estimated cell 
number better reflects in vivo growth characteristics of PKH
BRIGHT100
 and PKH
DIM1000
 fractions (N = number of tumors; cells = estimated number of injected cells, BRIGHT100: 100 
PKH
BRIGHT
-sorted cells; DIM100/1000: 100/1000 PKH
DIM
-sorted cells).
FIGURE 2.  The slow proliferating fraction is appreciable also ex vivo in NSCLC PDX. Cells derived from disaggregation of PDX 
were PKH labeled and reinjected subcutaneously in SCID mice (n = 4). PKH retaining CD133+ enriched cells are appreciable in 
tumors analyzed at different volumes (V1 = 250 mm
3, V2 = 1000 mm
3) in both PDX tested; PDX111 (A) and PDX73 (B).
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In Vivo Differentiation Therapy Partially 
Depletes CD133+ TICs, Leading to a Reduced 
Tumor Regrowth after Cisplatin Treatment
To investigate if ATRA-driven mobilization of a spe-
cific TICs compartment was also effective in vivo, we treated 
two NSCLC PDXs models (PDX73 and PDX111). ATRA 
alone slightly decreased the percentage of CD133+ cells 
(Supplementary 3D, SDC 1, http://links.lww.com/JTO/A843) 
without affecting tumor growth (Fig. 4A). Moreover, in both 
models, the combination of ATRA and CDDP had no syner-
gistic effect on tumor growth, but CD133+ enrichment due to 
CDDP treatment was strongly counteracted by combined treat-
ment in PDX73 (prevention of 100% of the CDDP-induced 
enrichment) and partially in PDX111 (prevention of 30% of 
the CDDP-induced enrichment, Fig. 4A). Interestingly, in both 
models, effects of combination therapy were mostly linked to a 
variation in the CD133+/CXCR4+ fraction (prevention of 40% 
of the CDDP-induced enrichment in PDX73 and of 125% in 
PDX111, Fig. 4B). This effect was mirrored by a decreased dis-
semination of human cells to lungs in mice receiving ATRA 
pretreatment (Fig. 4B). On the other hand, CD133+/CXCR4− 
cell levels were not affected by combined treatment (PDX73: 
untreated: 0.15%, CDDP: 0.3%. ATRA pretreatment: 0.35%; 
PDX111: untreated: 16%, CDDP: 20%. ATRA pretreatment: 
22%, Fig. 4B) and this was mirrored by a similar regrowth of 
CDDP only or combined-treated tumors after suspension of 
treatment (Fig. 4B). These findings indicate functional heteroge-
neity in the CD133+ TICs fraction with CD133+/CXCR4− cells 
(enriched within the PKH
BRIGHT
 fraction) mainly supporting 
local tumor growth, whereas CD133+/CXCR4+ cells (highly 
represented in the PKH
DIM
 fraction and susceptible to ATRA 
pretreatment) related to lung dissemination. Thus, differentiat-
ing therapy shows promising effects also in vivo, confirming the 
capability of ATRA to partially affect the TICs compartment by 
sensitizing CD133+/CXCR4+ cells to CDDP treatment resulting 
in a decreased lung dissemination, whereas local tumoral (re-)
growth and CD133+/CXCR4− cells are less affected.
Multiple Cycles of In Vivo ATRA and CDDP 
Treatment Significantly Reduce Tumor Volume
To investigate if the effects of the double treatment in 
vivo were permanent after multiple treatment cycles and to 
achieve a progressive exhaustion of the TICs reservoir, a serial 
transplantation experiment was performed. PDX111 resid-
ual tumors after treatment were cut in small pieces (3 mm), 
injected subcutaneously in a set of new mice and treated with 
ATRA and/or CDDP. After four serial transplantations (S4), a 
FIGURE 3.  In vitro ATRA pretreatment counteracts CDDP-derived TICs enrichment, except for the PKHBRIGHT CD133
+/CXCR4− 
fraction. PKH-labeled LT73 NSCLC cell line was treated with 10 µM CDDP alone or after ATRA (10 µM) pretreatment. ATRA 
pretreatment was able to counteract CDDP-induced PKH+ cells enrichment (A). A general enrichment of PKH+/CD133+ cells is 
appreciable after CDDP treatment (B, upper left box plot), this enrichment is striking for CD133+/CXCR4− cells. The increase of 
CD133+ cells is partially reverted by ATRA pretreatment especially in PKHDIM (lower left box plot) and PKHNEG (lower right box plot) 
fraction. Interestingly, CD133+/CXCR4+ cells are affected by CDDP and ATRA also in the PKHBRIGHT (upper right box plot) fraction, 
whereas CD133+/CXCR4− cells only in PKHDIM and PKHNEG fraction., t test p values are represented as: *p < 0.05, **p < 0.01,  
***p < 0.001. Also in ex vivo PDX-derived CTOS, the enrichment of CD133+ cells after CDDP is reverted by ATRA cotreatment, 
especially in the CD133+/CXCR4+ fraction (C).
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significant decrease in tumor growth of double treated mice 
compared with CDDP treated counterpart was achieved 
(V = 467 ± 160 mm3 and 864 ± 252 in double-treated and 
CDDP-treated, respectively, Fig. 5A). This difference in 
tumor growth was anticipated (at S3) by a lower percentage 
of CD133+ cells (3.8 ± 0.9% and 13 ± 1.32% in double-treated 
and CDDP-treated, respectively, Fig. 5A), which is mainly 
ascribed to the reduction of CD133+/CXCR4+ subset. After 
five treatment cycles, the effects of double treatment on tumor 
growth were still appreciable with a decrease of tumor volume 
in double-treated PDX. Interestingly, CD133+/CXCR4+ cell 
levels remained low at each cycle of differentiating therapy 
and this resulted in an appreciable and long-lasting (up to five 
serial transplants) decrease of disseminating cells in lungs of 
mice carrying PDXs (Fig. 5C). When double-treated tumors 
were transplanted into new mice and not retreated, a pro-
gressive increase in tumor growth was observable (Fig. 5B), 
which was accompanied by the constant increase of CD133+/
CXCR4− subset. Differentiating therapy with ATRA is there-
fore promising in controlling disseminating cells (CD133+/
CXCR4+), whereas CD133+/CXCR4− cells appear not to be 
completely exhausted after five treatment cycles.
DISCUSSION
TICs have been described in many tumor types for spe-
cific features, such as potential to initiate and maintain tumor 
growth and to give rise to all observed heterogeneous lineages, 
high expression of stem-related genes and of xenobiotic trans-
porter, and quiescence. These peculiar features suggest them 
as the prime suspect for tumor relapse or metastasis formation 
after chemotherapeutical treatment. We previously reported 
the presence of a cisplatin-resistant CD133+ cellular subpopu-
lation with stem-like characteristics in NSCLC cell lines and 
in vivo xenograft models. The dynamics of CSCs compart-
ment are beginning to be unraveled in the better understood 
leukemia models where hierarchy appears more delineated,29 
whereas little is known of this complexity in solid cancers.40 
However, resistance of CSC has already been reported to be 
linked to a slow rate of proliferation in ovarian,41 breast,42 and 
pancreatic43 cancer models and here, we demonstrated that 
the CD133+ residual fraction after CDDP treatment is mainly 
composed by slow proliferating label-(PKH67) retaining cells. 
The purpose of this study was to counteract the cisplatin resis-
tance of CD133+ cells, inducing a mobilization of these TICs 
to a less resistant phenotype using ATRA. ATRA was the first 
FIGURE 4.  In vivo ATRA pretreatment counteracts CDDP-derived enrichment of CD133+/CXCR4+ cells and lung dissemina-
tion in NSCLC PDX. In vivo ATRA treatment produces no effects in terms of tumor growth for both models tested, PDX111 and 
PDX73. Pretreating both models with ATRA and CDDP gives no benefits in terms of tumor growth compared with CDDP only 
treatment (A). At the end of treatment, CD133+/CXCR4+ cell percentage in the residual tumors are lower compared with CDDP 
treated tumors, and this correlates with a lower lung dissemination of tumoral cells, whereas CD133+/CXCR4- cell levels are 
unaffected by ATRA pretreatment resulting in a similar regrowth rate of the treated tumors (B).
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differentiation agent found to be successful in the treatment of 
acute promyelocytic leukemia where it promotes differentia-
tion of promyelocytic to myeloid cells, blocked by the chimeric 
protein product of the fusion gene PML/RARα.44 Retinoic acid 
has been reported to be involved in processes of lung embryo-
genesis with an accumulation within the lung during organ 
development and a temporally association with the process of 
alveolar septation. The importance of retinoids in the genera-
tion of alveoli is confirmed by studies involving retinoid recep-
tor knock-out animals45 as well as by in vitro experiments on 
human cell lines demonstrating that retinoic acid can regulate 
an array of cellular and molecular pathways in lung remodel-
ing.46 Moreover, a randomized phase II trial indicated that add-
ing ATRA to chemotherapy could increase response rate and 
progression-free survival in patients with advanced (IIIb–IV) 
NSCLC.47 On the basis of these data, we hypothesized that 
a differentiating therapy with retinoids could play a role in 
lung tumor growth, promoting the differentiation to a CDDP 
susceptible state of CD133+ NSCLC TICs. A partial rever-
sion of CDDP-induced enrichment of CD133+ cells in vitro 
FIGURE 5.  Multiple cycles of ATRA pretreatment in a serial transplantation assay leads to a long-lasting reduction of lung 
dissemination and CD133+/CXCR4+ cell fraction. In PDX111 tumors, explanted from mice after treatments and reimplanted 
subcutaneously in new SCID mice, a significant decrease of tumor growth is appreciable after four passages of serial transplants, 
but this effect attenuates in the following passage: S4,VCDDP = 864 ± 252 mm
3, VATRA+CDDP = 467 ± 160 mm
3, n = 8, p = 0.0272; S5,  
VCDDP = 991 ± 168 mm
3, VATRA+CDDP = 658 ± 135 mm
3, n = 8, p = 0.07. These effects are preceded by a reduction, already at S3, of 
CD133+ percentage in double treated tumor compared with CDDP treated (S3 %CD133+CDDP = 13 ± 1.32%, %CD133
+
ATRA+CDDP= 
3.8 ± 0.9%). Interestingly, CD133+/CXCR4− cell levels reflect this trend of local growth throughout the serial passages, whereas 
CD133+/CXCR4+ cells levels are constantly low after third passage (A). If tumors were serially transplanted after double treat-
ment but no more treated, tumor growth were significantly higher than in treated ones (S4,VNOT TREATED = 998 ± 228 mm
3, 
VATRA+CDDP = 467 ± 160 mm
3, n = 8, p = 0.0128; S5, VNOT TREATED = 1170 ± 174 mm
3, VATRA+CDDP = 658 ± 135 mm
3,  
n = 8, p = 0.10]. Again, these effects are mirrored by CD133+/CXCR4− cell levels and not by CD133+/CXCR4+ cells, whose levels 
remain low also when treatment is interrupted (B). t test p values are represented as: *p < 0.05, **p < 0.01, ***p < 0.001. At fifth 
serial passage, CD133+/CXCR4+ cell levels and lung dissemination of tumoral cells but not CD133+/CXCR4- cell levels are perma-
nently controlled by ATRA pretreatment (C).
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was observed after exposure to the differentiating compound. 
However, ATRA does not completely affect CD133+ cells, sug-
gesting that this subpopulation represents a nonhomogeneous 
TICs reservoir. We demonstrated TICs heterogeneity also in 
terms of quiescence; indeed, in PKH labeling experiments, 
CD133+ cells are represented in the entire PKH label spectrum, 
but PKH
BRIGHT
 cells are highly enriched for CD133+/CXCR4− 
population, whereas CD133+/CXCR4+ cells are more repre-
sented in the PKH
DIM
 fraction. Interestingly, the entire spectrum 
of PKH retaining CD133+ cells are CDDP resistant, but ATRA 
is able to nick in the PKH
DIM
 group making CD133+/CXCR4+ 
cells more susceptible to chemotherapeutics in in vitro, ex vivo, 
and in vivo experiments. Moreover, ATRA treatment alone was 
able to induce a general but reduced decrease of CD133+ cell 
percentages as well as a slight decrease in expression levels of a 
panel of stem-related genes and these effects reached statistical 
significance in the PKH+/CD133+/CXCR4+ fraction, confirm-
ing a role of the differentiating agent ATRA in the mobilization 
of a specific subset of quiescent TICs. A functional heteroge-
neity of CD133+ cells, according to CXCR4 expression, has 
also been demonstrated in different tumor types; in particu-
lar, CD133+/CXCR4+ cells have been indicated as a subset of 
CD133+ TICs with high metastatic potential in pancreatic can-
cer48 and as a marker for lymph node metastasis in colon cancer 
models.49 Moreover, the functional role of CXCR4/CXLC12 
axis in cell mobilization, dissemination, and metastasis forma-
tion has already been elucidated.50 Based on PKH retaining 
ability, we can hypothesize a precise hierarchy within CD133+ 
TICs, with CD133+/CXCR4− (PKH
BRIGHT
) cells representing the 
pluripotent CSCs and CD133+/CXCR4+ (PKH
DIM
) cells repre-
senting a pool of multipotent progenitors derived from them. 
In vivo experiments corroborate this hypothesis, indeed a low 
number of PKH
BRIGHT
, but not PKH
DIM
 cells is able to give rise to 
a completely developed tumor if xenografted in immunocom-
promised mice. Interestingly, injection of 103PKH
DIM
 cells (cor-
responding to about 40 CD133+/CXCR4− cells) led to a delayed 
tumor growth compared with 102 PKH
BRIGHT
 cells (correspond-
ing to a similar amount of CD133+/CXCR4− cells), suggesting 
a higher tumorigenic potential of the most quiescent subset of 
CD133+/CXCR4− cells compared with the same population 
in the PKH
DIM
 fraction. However, in the PKH
BRIGHT
 fraction 
CD133+/CXCR4- cells are represented at high purity (repre-
senting more than 30% of the fraction), whereas in the PKH
DIM
 
the same number of CD133+/CXCR4− cells is contained within 
a higher number of non-TICs. It is therefore also possible that 
interference of non-TICs with TICs in the early phases of tumor 
initiation could be responsible for the delayed and decreased 
tumorigenicity. High level of complexity within TICs niche was 
also confirmed by in vitro ATRA pretreatment which counter-
acted TICs enrichment after CDDP challenge differently in dif-
ferent compartments: increase of CD133+/CXCR4+ was in fact 
prevented in both PKH fractions, whereas increase of CD133+/
CXCR4− cells was efficiently prevented in PKH
DIM
 but not in 
PKH
BRIGHT
 fraction. Moreover, in vivo ATRA pretreatment was 
not able to affect CD133+/CXCR4- cells, resulting in a continu-
ous tumor growth at every passage in the serial transplantation 
assay. This suggests that quiescent CD133+/CXCR4- cells repre-
sent the TICs subset which is able, alone, to regenerate a hetero-
geneous tumor. Conversely, susceptibility of CD133+/CXCR4+ 
cells to ATRA pretreatment leads to a progressive eradication 
of this TICs fraction in the PDX serial transplantation assay, 
and this is correlated with a decrease of tumor dissemination to 
murine lungs, indicating a role of double positive cells in tumor 
spread from subcutaneous implants. Interestingly, CXCR4 
expression has been already linked to a higher metastatic poten-
tial of NSCLC.51,52 Thus ATRA, interfering with TICs dynam-
ics and therefore counteracting cisplatin resistance of CD133+/
CXCR4+ cells, can have a therapeutic impact for lung cancers 
in terms of reduction of the metastatic potential. Moreover, dif-
ferential activity of ATRA on specific subsets within the CSC 
compartment allows us to describe, for the first time, the hetero-
geneity of CD133+ TICs. It remains mandatory to better under-
stand the TICs compartment’s dynamics, and in particular the 
equilibrium between CD133+/CXCR4− and CD133+/CXCR4+ 
cells, to specifically target the quiescent niche or at least to 
block its mobilization, whereas disseminating progenitors can 
be affected and controlled by ATRA treatment in combination 
with standard chemotherapy.
ACKNOWLEDGMENTS
The authors thank the help of AIRC (Associazione 
Italiana per la Ricerca sul Cancro: IG13403 to L.R.; IG11991 
to G.S.), European Community Integrated Project 037665 
“CHEMORES” (to G.S.) and the European Community 
Seventh Framework Programme (FP7/2007–2013) 
under Grant Agreement No. HEALTH-F2-2010–258677 
(Collaborative Project CURELUNG to L.R.).
REFERENCES
 1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J 
Clin 2011;61:69–90.
 2. Kim ES, Lee JJ, He G, et al. Tissue platinum concentration and tumor 
response in non-small-cell lung cancer. J Clin Oncol 2012;30:3345–3352.
 3. Stewart DJ. Tumor and host factors that may limit efficacy of chemother-
apy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 
2010;75:173–234.
 4. Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin 
resistance. Oncogene 2012;31:1869–1883.
 5. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conven-
tional therapy display mesenchymal as well as tumor-initiating features. 
Proc Natl Acad Sci USA 2009;106:13820–13825.
 6. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell 
biology to cancer. Nat Rev Cancer 2003;3:895–902.
 7. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in can-
cer: Cancer stem cells versus clonal evolution. Cell 2009;138:822–829.
 8. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic cell. Nat Med 
1997;3:730–737.
 9. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell 
in human brain tumors. Cancer Res 2003;63:5821–5828.
 10. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise 
from pediatric brain tumors. Proc Natl Acad Sci USA 2003;100:15178–15183.
 11. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of 
tumorigenic, stem-like neural precursors from human glioblastoma. 
Cancer Res 2004;64:7011–7021.
 12. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating 
human melanomas. Nature 2008;451:345–349.
 13. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. 
Prospective identification of tumorigenic breast cancer cells. Proc Natl 
Acad Sci USA 2003;100:3983–3988.
 14. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like 
cells contribute to the aggressive behavior of human epithelial ovarian 
cancer. Cancer Res 2005;65:3025–3029.
1036 Copyright © 2015 by the International Association for the Study of Lung Cancer
Moro et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 7, July 2015
 15. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective 
identification of tumorigenic prostate cancer stem cells. Cancer Res 
2005;65:10946–10951.
 16. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expan-
sion of human colon-cancer-initiating cells. Nature 2007;445:111–115.
 17. O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell 
capable of initiating tumour growth in immunodeficient mice. Nature 
2007;445:106–110.
 18. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization 
of human colorectal cancer stem cells. Proc Natl Acad Sci USA 
2007;104:10158–10163.
 19. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumori-
genic lung cancer stem cell population. Cell Death Differ 2008;15:504–514.
 20. Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer 
CD133+ cells display stem-like features and are spared by cisplatin treat-
ment. Proc Natl Acad Sci USA 2009;106:16281–16286.
 21. Koren A, Motaln H, Cufer T. Lung cancer stem cells: A biological and 
clinical perspective. Cell Oncol (Dordr) 2013;36:265–275.
 22. Freitas DP, Teixeira CA, Santos-Silva F, Vasconcelos MH, Almeida GM. 
Therapy-induced enrichment of putative lung cancer stem-like cells. Int J 
Cancer 2014;134:1270–1278.
 23. Richichi C, Brescia P, Alberizzi V, Fornasari L, Pelicci G. Marker-
independent method for isolating slow-dividing cancer stem cells in 
human glioblastoma. Neoplasia 2013;15:840–847.
 24. Pece S, Tosoni D, Confalonieri S, et al. Biological and molecular hetero-
geneity of breast cancers correlates with their cancer stem cell content. 
Cell 2010;140:62–73.
 25. Kleffel S, Schatton T. Tumor dormancy and cancer stem cells: Two sides 
of the same coin? Adv Exp Med Biol 2013;734:145–179.
 26. Bartucci M, Svensson S, Romania P, et al. Therapeutic targeting of 
Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ 
2012;19:768–778.
 27. Zeuner A, Francescangeli F, Contavalli P, et al. Elimination of quiescent/
slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small 
cell lung cancer. Cell Death Differ 2014;21:1877–1888.
 28. Essers MA, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant 
haematopoietic stem cells in vivo. Nature 2009;458:904–908.
 29. Essers MA, Trumpp A. Targeting leukemic stem cells by breaking their 
dormancy. Mol Oncol 2010;4:443–450.
 30. Connolly RM, Nguyen NK, Sukumar S. Molecular pathways: Current 
role and future directions of the retinoic acid pathway in cancer preven-
tion and treatment. Clin Cancer Res 2013;19:1651–1659.
 31. Niu CS, Li MW, Ni YF, et al. Effect of all-trans retinoic acid on the pro-
liferation and differentiation of brain tumor stem cells. J Exp Clin Cancer 
Res 2010;29:113.
 32. Zhang Y, Guan DX, Shi J, et al. All-trans retinoic acid potentiates the 
chemotherapeutic effect of cisplatin by inducing differentiation of tumor 
initiating cells in liver cancer. J Hepatol 2013;59:1255–1263.
 33. Friedman MD, Jeevan DS, Tobias M, Murali R, Jhanwar-Uniyal M. 
Targeting cancer stem cells in glioblastoma multiforme using mTOR 
inhibitors and the differentiating agent all-trans retinoic acid. Oncol Rep 
2013;30:1645–1650.
 34. Moro M, Bertolini G, Tortoreto M et al. Patient-derived xenografts of 
non-small cell lung cancer: Resurgence of an old model for investigation 
of modern concepts of tailored therapy and cancer stem cells. J Biomed 
Biotechnol 2012;2012:568567.
 35. Kondo J, Endo H, Okuyama H, et al. Retaining cell-cell contact 
enables preparation and culture of spheroids composed of pure pri-
mary cancer cells from colorectal cancer. Proc Natl Acad Sci USA 
2011;108:6235–6240.
 36. Bertolini G, Moro M, Tortoreto M et al. The subset of CD133+/CXCR4+/
EpCAM(−) cancer initiating cells is responsible for lung tumor metastatic 
spreading. Eur.J Cancer 2012;48:S90. Abstract No 372.
 37. Kusumbe AP, Bapat SA. Cancer stem cells and aneuploid populations 
within developing tumors are the major determinants of tumor dormancy. 
Cancer Res 2009;69:9245–9253.
 38. Basu D, Nguyen TT, Montone KT, et al. Evidence for mesenchymal-like 
sub-populations within squamous cell carcinomas possessing chemore-
sistance and phenotypic plasticity. Oncogene 2010;29:4170–4182.
 39. Rothwell DG, Li Y, Ayub M, et al. Evaluation and validation of a robust 
single cell RNA-amplification protocol through transcriptional profiling 
of enriched lung cancer initiating cells. BMC Genomics 2014;15:1129.
 40. Pine SR, Ryan BM, Varticovski L, Robles AI, Harris CC. 
Microenvironmental modulation of asymmetric cell division in human 
lung cancer cells. Proc Natl Acad Sci USA 2010;107:2195–2200.
 41. Gao MQ, Choi YP, Kang S, Youn JH, Cho NH. CD24+ cells from hier-
archically organized ovarian cancer are enriched in cancer stem cells. 
Oncogene 2010;29:2672–2680.
 42. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain 
stem-like cells that self-renew, give rise to phenotypically diverse progeny 
and survive chemotherapy. Breast Cancer Res 2008;10:R25.
 43. Dembinski JL, Krauss S. Characterization and functional analysis of a 
slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. 
Clin Exp Metastasis 2009;26:611–623.
 44. Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leuke-
mia. Oncogene 2001;20:7140–7145.
 45. McGowan S, Jackson SK, Jenkins-Moore M et al. Mice bearing deletions 
of retinoic acid receptors demonstrate reduced lung elastin and alveolar 
numbers. Am J Respir Cell Mol Biol 2000;23:162–167.
 46. Mao JT, Tashkin DP, Belloni PN et al. All-trans retinoic acid modulates 
the balance of matrix metalloproteinase-9 and tissue inhibitor of metal-
loproteinase-1 in patients with emphysema. Chest 2003;124:1724–1732.
 47. Arrieta O, González-De la Rosa CH, Aréchaga-Ocampo E, et al. 
Randomized phase II trial of all-trans-retinoic acid with chemo-
therapy based on paclitaxel and cisplatin as first-line treatment in 
patients with advanced non-small-cell lung cancer. J Clin Oncol 
2010;28:3463–3471.
 48. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer 
stem cells determine tumor growth and metastatic activity in human pan-
creatic cancer. Cell Stem Cell 2007;1:313–323.
 49. Silinsky J, Grimes C, Driscoll T, et al. CD 133+ and CXCR4+ colon cancer 
cells as a marker for lymph node metastasis. J Surg Res 2013;185:113–118.
 50. Domanska UM, Kruizinga RC, Nagengast WB et al. A review on 
CXCR4/CXCL12 axis in oncology: No place to hide. Eur J Cancer 
2013;49:219–230.
 51. Wang L, Wang Z, Liu X, Liu F. High-level C-X-C chemokine receptor type 
4 expression correlates with brain-specific metastasis following complete 
resection of non-small cell lung cancer. Oncol Lett 2014;7:1871–1876.
 52. Xie S, Zeng W, Fan G, et al. Effect of CXCL12/CXCR4 on increasing 
the metastatic potential of non-small cell lung cancer in vitro is inhibited 
through the downregulation of CXCR4 chemokine receptor expression. 
Oncol Lett 2014;7:941–947.
